Literature DB >> 1312907

Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.

R Leone1, M E Fracasso, E Soresi, G Cimino, M Tedeschi, D Castoldi, V Monzani, L Colombi, T Usari, A Bernareggi.   

Abstract

The kinetics of platinum (Pt) was studied in 12 patients suffering from non-small-cell lung cancer or pleural mesothelioma. Each subject received an infusion of cisplatin (CDDP, 80 mg/m2), and six patients were pretreated with glutathione (GSH, 2.5 g given i.v.) at 15 min prior to the cisplatin infusion. After a 3- to 4-week interval, all patients were given a second course of treatment on the same schedule. A biexponential model was fitted to plasma concentrations of total and ultrafilterable Pt. The excretion of Pt in urine was evaluated during the first 48 h after the CDDP infusion. Following the administration of CDDP alone or with GSH pretreatment, the pharmacokinetic parameters of Pt did not significantly differ between the treatments. Also, the unbound fraction determined at each sampling time did not vary significantly between the treatments. However, it is noteworthy that the mean values obtained for the terminal half-life, the volume of distribution, the renal clearance, the percentage of the dose excreted in the urine, and the mean residence time of total Pt were higher in patients who had been pretreated with GSH, suggesting that GSH might increase both the rate of Pt elimination and the extent of Pt distribution and, as a consequence of the latter, might prolong the residence time of Pt in the body. In addition, the unbound fraction of Pt from the 4th to the 48th was higher following the first dose of CDDP+GSH than after treatment with CDDP alone. Because of the rather high variability in the values of the parameters obtained, further work is planned using a larger number of patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312907     DOI: 10.1007/bf00686008

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Glutathione and detoxification.

Authors:  M Tedeschi; S Bohm; F Di Re; S Oriana; G B Spatti; S Tognella; F Zunino
Journal:  Cancer Treat Rev       Date:  1990-09       Impact factor: 12.111

2.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; A A Hart; H E Gall; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1984-03

3.  Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug.

Authors:  F Zunino; G Pratesi; A Micheloni; E Cavalletti; F Sala; O Tofanetti
Journal:  Chem Biol Interact       Date:  1989       Impact factor: 5.192

Review 4.  Cisplatin pharmacokinetics: applications of a physiological model.

Authors:  F F Farris; R L Dedrick; F G King
Journal:  Toxicol Lett       Date:  1988-10       Impact factor: 4.372

5.  Kinetics of platinum in cancer patients treated with cisplatin at different doses.

Authors:  M E Fracasso; P Apostoli; G Benoni; A Bonetti; C Griso; R Leone
Journal:  Drugs Exp Clin Res       Date:  1987

6.  High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine.

Authors:  S Aebi; R Assereto; B H Lauterburg
Journal:  Eur J Clin Invest       Date:  1991-02       Impact factor: 4.686

Review 7.  High-dose cisplatin therapy in ovarian cancer.

Authors:  R F Ozols; R C Young
Journal:  Semin Oncol       Date:  1985-12       Impact factor: 4.929

8.  Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.

Authors:  F Di Re; S Bohm; S Oriana; G B Spatti; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin.

Authors:  F Tosetti; M Rocco; R A Fulco; S Chiara; M Bruzzone; E Campora; M Esposito
Journal:  Anticancer Res       Date:  1988 May-Jun       Impact factor: 2.480

10.  Protective effect of reduced glutathione against cis-dichlorodiammine platinum (II)-induced nephrotoxicity and lethal toxicity.

Authors:  F Zunino; O Tofanetti; A Besati; E Cavalletti; G Savi
Journal:  Tumori       Date:  1983-04-30
  10 in total
  6 in total

Review 1.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 2.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

3.  Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.

Authors:  Cynthia S Lancaster; Chaoxin Hu; Ryan M Franke; Kelly K Filipski; Shelley J Orwick; Zhaoyuan Chen; Zhili Zuo; Walter J Loos; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2010-09-21       Impact factor: 12.531

Review 4.  Pharmacokinetic drug interactions with anticancer drugs.

Authors:  P M Loadman; M C Bibby
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 5.  The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.

Authors:  G A Hospers; E A Eisenhauer; E G de Vries
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

Review 6.  Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - Exploring the armoury of obscurity.

Authors:  Kanchanlata Singh; Mustansir Bhori; Yasar Arfat Kasu; Ganapathi Bhat; Thankamani Marar
Journal:  Saudi Pharm J       Date:  2017-12-19       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.